Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Eton Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was $1,189.0 Mil.
Eton Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals EV-to-EBIT Related Terms
Eton Pharmaceuticals EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Eton Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eton Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's EV-to-EBIT falls into.
Eton Pharmaceuticals's current Enterprise Value is $1,614.3 Mil.
Eton Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals (ETON) has a EV-to-EBIT of 98.98 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eton Pharmaceuticals and its competitors. According to the industry distribution chart, Eton Pharmaceuticals ranks #675 out of 682 companies in the Drug Manufacturers industry, placing it in the top 99%.
Is Eton Pharmaceuticals' EV-to-EBIT too high?
Eton Pharmaceuticals' current EV-to-EBIT is 98.98. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Eton Pharmaceuticals' value of 98.98 is 524.3% above this industry median. Based on the distribution chart, Eton Pharmaceuticals ranks #675 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eton Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eton Pharmaceuticals' EV-to-EBIT compare to COLL and ALVO?
According to the Drug Manufacturers industry distribution chart, Eton Pharmaceuticals ranks #675 out of 682 companies for EV-to-EBIT. This places Eton Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.86. Eton Pharmaceuticals' value of 98.98 is 524.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eton Pharmaceuticals's current EV-to-EBIT of 98.98 is 524.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Eton Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eton Pharmaceuticals's current EV-to-EBIT is 98.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eton Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Eton Pharmaceuticals (ETON) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.98, compared to a current price of $58.51 — trading 192.8% above its estimated fair value. The current EV-to-EBIT is 98.98 and 524.3% above the Drug Manufacturers industry median of 15.86. Eton Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Eton Pharmaceuticals (ETON), the current EV-to-EBIT is 98.98 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eton Pharmaceuticals (ETON) Overvalued in 2026?
Based on GuruFocus' analysis, Eton Pharmaceuticals stock appears to be overvalued.
The current stock price of $58.51 is trading 192.8% above its estimated GF Value™ of $19.98.
GuruFocus considers Eton Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ETON:
EV-to-EBIT: 98.98
GF Value™: $19.98 vs. price of $58.51 (192.8% above fair value)
Industry Position: 524.3% above the Drug Manufacturers median (#675 of 682)
No single metric tells the full story. See the ETON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
57GF Score
Get the complete analysis for ETON
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETON has been successfully added to your 
